Pfizer issues Robitussin recall of cough syrup due to labeling errors

Posted
by John Chapman

Pfizer is voluntarily recalling its cough syrup medicine, Robitussin DM product, due to errors in its labeling, according to the Food and Drug Administration. Robitussin DM product contains Dextromethorphan HBr 15mg and Guaifenessin 100mg per 5ml.

FDA officer-in-charge and assistant secretary of health Nicolas Lutero III said the continuous distribution of the said product present health risk to the consuming sector of the public. “Anyone who may have bought the affected products are advised to discontinue using the same and immediately coordinate with Pfizer,” Lutero added.

The label indicated one teaspoonful or 2.5 ml for children between two and six years old when the correct dosage should be only half a teaspoon for every six hours, according to FDA officials. The FDA posted an online advisory (PDF) concerning the Robitussin recall on its website.

Prescription drug labeling errors are a dangerous problem. A July 2006 IOM report found that major problems with naming labeling and packaging cause of 33% of medication errors, including 30% of fatalities due to medication errors.

The lawyers at Heygood, Orr & Pearson have made it a career priority to hold drug manufacturers accountable and responsible for their actions. We have the resources and experience to protect a person’s rights and the rights of their loved ones against irresponsible pharmaceutical companies and physicians.

If you or a loved one has experienced the tragedy of losing a family member as a result of prescription medicine errors, you and your family deserve answers to your questions. Contact the law firm Heygood, Orr & Pearson for a free consultation so we can help you determine the best way to protect your legal rights and interests. You can reach us by calling our toll-free hotline at 1-877-446-9001, or by filling out our free case evaluation form.